hero-mobile
Pulmonary arterial hypertension (PAH, WHO Group I) is a silently progressive disease1

Before 
Progression
 Takes More Away

Add Uptravi® Earlier in FC II and FC III

Uptravi®: Proven to Delay PAH Progression
  • TIME-FROM-DIAGNOSIS SUBGROUPS

    View time-from-diagnosis subgroup analyses

    SEE THE DATA
  • TRIPLE-COMBINATION SUBGROUP

    View triple-combination subgroup analyses

    SEE THE DATA
  • CTD SUBGROUP

    View CTD subgroup analysis

    SEE THE DATA
  • OPEN-LABEL EXTENSION

    View the open-label extension data

    SEE THE DATA
  • Enroll a Patient

    Get patients started on UPTRAVI®

    Enroll Now
  • Support for patients during treatment

    Help patients start on therapy and set expectations for the dose adjustment phase

    Get Help Now
  • MECHANISM OF ACTION

    See how UPTRAVI® targets the prostacyclin pathway in PAH

    WATCH THE VIDEO